Harvard Bioscience Inc (HBIO)
3.75
+0.41
(+12.28%)
USD |
NASDAQ |
Mar 28, 16:00
3.85
+0.10
(+2.67%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 158.21M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -43.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.381 |
| Price to Book Value | 2.191 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6484 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 78.65% |
News
Headline
Wire
Time (ET)
Yahoo
03/16 09:25
MT Newswires
03/09 07:02
MT Newswires
03/09 07:01
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 08:00 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | 0.05 | -- | |
| 03/09/2023 | 08:00 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 03/09/2023 | -- | Results | Q4 2022 | 0.04 | 0.01 | 700.0% | |
| 11/08/2022 | 16:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 11/08/2022 | -- | Results | Q3 2022 | -0.01 | 0.06 | -118.2% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 0.05 | 0.06 | -9.09% |
*Estimated Date/Time
Earnings
Profile
Edit
| Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States. |
| URL | https://www.harvardbioscience.com |
| Investor Relations URL | https://investor.harvardbioscience.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 27, 2023.
Fundamentals
| Revenue (TTM) | 113.34M |
| Total Expenses (TTM) | 120.50M |
| Net Income (TTM) | -9.516M |
| Total Assets (Quarterly) | 145.36M |
| Total Liabilities (Quarterly) | 73.14M |
| Shareholders Equity (Quarterly) | 72.22M |
| Cash from Operations (TTM) | 1.152M |
| Cash from Investing (TTM) | -1.59M |
| Cash from Financing (TTM) | -2.837M |
Ratings
Profile
Edit
| Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States. |
| URL | https://www.harvardbioscience.com |
| Investor Relations URL | https://investor.harvardbioscience.com |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Equity Style | Small Cap/Value |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Mar. 09, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| AFMCX | 439131.0 USD | 0.94% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| HBIO Tweets |